NB3 Stock Overview Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Neurocrine Biosciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Neurocrine Biosciences Historical stock prices Current Share Price US$111.10 52 Week High US$147.45 52 Week Low US$100.85 Beta 0.33 1 Month Change -19.08% 3 Month Change 0.36% 1 Year Change -9.93% 3 Year Change 49.57% 5 Year Change 18.39% Change since IPO 264.26%
Recent News & Updates
Neurocrine Biosciences, Inc. Provides Sales Guidance for the Full Year 2025 Feb 07
Neurocrine Biosciences, Inc. to Report Q4, 2024 Results on Feb 06, 2025 Jan 31
Andrew Ratz Joins Neurocrine Biosciences, Inc. as Senior Vice President of Drug Development, Delivery and Device Jan 24
Neurocrine Biosciences, Inc. Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia Jan 09
Neurocrine Biosciences, Inc. Announces Commercial Availability of CRENESSITY (Crinecerfont) for Children and Adults with Classic Congenital Adrenal Hyperplasia Dec 20
Neurocrine Biosciences, Inc. Announces FDA Approval of Crenessity (Crinecerfont), A First-In-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia Dec 14 See more updates
Neurocrine Biosciences, Inc. Provides Sales Guidance for the Full Year 2025 Feb 07
Neurocrine Biosciences, Inc. to Report Q4, 2024 Results on Feb 06, 2025 Jan 31
Andrew Ratz Joins Neurocrine Biosciences, Inc. as Senior Vice President of Drug Development, Delivery and Device Jan 24
Neurocrine Biosciences, Inc. Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia Jan 09
Neurocrine Biosciences, Inc. Announces Commercial Availability of CRENESSITY (Crinecerfont) for Children and Adults with Classic Congenital Adrenal Hyperplasia Dec 20
Neurocrine Biosciences, Inc. Announces FDA Approval of Crenessity (Crinecerfont), A First-In-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia Dec 14
Neurocrine Biosciences, Inc. Presents New KINECT-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health with INGREZZA (Valbenazine) Capsules Nov 08 Neurocrine Biosciences, Inc. Presents Breadth of Data Demonstrating Holistic Improvements over Time in Patients with Tardive Dyskinesia Following Treatment with INGREZZA (Valbenazine) Capsules
Third quarter 2024 earnings released: EPS: US$1.28 (vs US$0.85 in 3Q 2023) Nov 01 Neurocrine Biosciences, Inc. (NasdaqGS:NBIX) announces an Equity Buyback for $300 million worth of its shares. Oct 30
Neurocrine Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 10
Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia Sep 13
New minor risk - Share price stability Aug 29
Investor sentiment deteriorates as stock falls 18% Aug 29
Independent Chairman of the Board recently sold €1.9m worth of stock Aug 18
Second quarter 2024 earnings released: EPS: US$0.65 (vs US$0.98 in 2Q 2023) Aug 02
Neurocrine Biosciences, Inc. Raises Sales Guidance for the Full Year of 2024 Aug 01
Neurocrine Biosciences, Inc. Launches INGreZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing Jul 18
Neurocrine Biosciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 12
Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH Jul 01 Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences Announces CEO Changes May 30
Neurocrine Biosciences Announces CEO Changes May 29
Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis May 23
Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 May 15
Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 May 11
Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults May 09
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 May 08
Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024 May 03
First quarter 2024 earnings released: EPS: US$0.43 (vs US$0.79 loss in 1Q 2023) May 02
Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules May 02
Insufficient new directors May 01
Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community Apr 25
Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder Apr 23 Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024
Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder Apr 03
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults Mar 28
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment Feb 28
New minor risk - Shareholder dilution Feb 13
Full year 2023 earnings released: EPS: US$2.56 (vs US$1.61 in FY 2022) Feb 08
Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024 Feb 07
Neurocrine Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 07, 2024 Jan 18 Sosei Heptares’ Partner Neurocrine Biosciences Confirms Its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation Nov 14
Neurocrine Biosciences, Inc. Reports Update on the Phase 2 Clinical Trial Nov 11
Neurocrine Biosciences® Presents Ingrezza® (Valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated with Huntington's Disease Through Week 50 At Huntington Study Group 2023 Nov 03
Neurocrine Biosciences, Inc. Provides Sales Guidance for the Year 2023 Nov 01
Third quarter 2023 earnings released: EPS: US$0.85 (vs US$0.71 in 3Q 2022) Nov 01
Neurocrine Biosciences, Inc. to Report Q3, 2023 Results on Oct 31, 2023 Oct 11
Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Application for Ingrezza®? (Valbenazine) Oral Granules Sprinkle Formulation Sep 15
Neurocrine Biosciences, Inc. Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH) Sep 14
Neurocrine Biosciences Inc. Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults Sep 12
Neurocrine Biosciences, Inc. Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders Demonstrating Comparable Improvement over Time in Tardive Dyskinesia Severity and Impact Following Treatment with INGREZZA (Valbenazine) Capsules Aug 30
Neurocrine Biosciences, Inc. Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease Aug 29
Neurocrine Biosciences, Inc. Announces FDA Approval of INGreZZA (valbenazine) Capsules for the Treatment of Chorea Associated with Huntington's Disease Aug 19
Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023 Aug 03
Second quarter 2023 earnings released: EPS: US$0.98 (vs US$0.18 loss in 2Q 2022) Aug 02
Neurocrine Biosciences, Inc. Announces Retirement of Eiry W. Roberts as Chief Medical Officer Jul 14 Neurocrine Biosciences, Inc. to Report Q2, 2023 Results on Aug 01, 2023
Neurocrine Biosciences, Inc. Presents INGreZZA(R) (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate Jun 03
Neurocrine Biosciences, Inc. Announces Publication of Full KINECT(TM)-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in the Lancet Neurology May 20
Neurocrine Biosciences, Inc. Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023 May 13
Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023 May 04
First quarter 2023 earnings released: US$0.79 loss per share (vs US$0.15 profit in 1Q 2022) May 03
Insufficient new directors Mar 01
Full year 2022 earnings released: EPS: US$1.61 (vs US$0.95 in FY 2021) Feb 07
Neurocrine Biosciences, Inc. to Report Q4, 2022 Results on Feb 06, 2023 Jan 18
Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as A Treatment for Chorea Associated with Huntington Disease Dec 24
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-And-Wave During Sleep Dec 08
Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022 Nov 04
Third quarter 2022 earnings released: EPS: US$0.71 (vs US$0.24 in 3Q 2021) Nov 02
Neurocrine Biosciences, Inc. Provides Sales Guidance for the Full-Year 2022 Nov 02
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia Oct 28
Neurocrine Biosciences, Inc. Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022 Oct 25
Neurocrine Biosciences, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 12
Neurocrine Biosciences, Inc. Announces That Dr. Ingrid Delaet Will Join the Company's Executive Management Team as Chief Regulatory Officer Effective October 1, 2022 Sep 30 Neurocrine Biosciences Presents INGREZZA(R) (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022 Sep 21
Neurocrine Biosciences, Inc. Announces to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians At 2022 MDS International Congress
Neurocrine Biosciences, Inc. (NasdaqGS:NBIX) agreed to acquire Diurnal Group plc (AIM:DNL) for £46.8 million. Aug 31
Neurocrine Biosciences, Inc. Raises Sales Guidance for the Full Year of Fiscal 2022 Aug 06
Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.45 profit in 2Q 2021) Aug 05
Neurocrine Biosciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 15
Neurocrine Biosciences, Inc. Presents Data on Sleep Disturbances and Off Time in Patients with Parkinson's Disease and Motor Fluctuations At Sleep 2022 Jun 07
First quarter 2022 earnings released: EPS: US$0.15 (vs US$0.34 in 1Q 2021) May 05
Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2022 May 05
Neurocrine Biosciences, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 14
Neurocrine Biosciences, Inc., Annual General Meeting, May 18, 2022 Apr 09
Neurocrine Biosciences Presents Phase 3 Data for Kinect-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease At AAN 2022 Apr 03
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 12 Shareholder Returns NB3 DE Biotechs DE Market 7D -5.4% -3.2% 2.7% 1Y -9.9% -7.9% 17.0%
See full shareholder returns
Return vs Market: NB3 underperformed the German Market which returned 17% over the past year.
Price Volatility Is NB3's price volatile compared to industry and market? NB3 volatility NB3 Average Weekly Movement 6.6% Biotechs Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.1% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: NB3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: NB3's weekly volatility (7%) has been stable over the past year.
About the Company Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions.
Show more Neurocrine Biosciences, Inc. Fundamentals Summary How do Neurocrine Biosciences's earnings and revenue compare to its market cap? NB3 fundamental statistics Market cap €10.93b Earnings (TTM ) €325.26m Revenue (TTM ) €2.24b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NB3 income statement (TTM ) Revenue US$2.36b Cost of Revenue US$765.10m Gross Profit US$1.59b Other Expenses US$1.25b Earnings US$341.30m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/16 13:39 End of Day Share Price 2025/02/14 00:00 Earnings 2024/12/31 Annual Earnings 2024/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Neurocrine Biosciences, Inc. is covered by 43 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Martha Freitag Argus Research Company Brian Skorney Baird Ishan Majumdar Baptista Research
Show 40 more analysts 
